Home > Insider Trading > Filing (0001437749-22-008915)

Filing Details

Accession Number:: 0001437749-22-008915
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-04-13 21:19:57
Reporting Period:: 2022-04-11

Accepted Time:: 2022-04-13 21:19:57
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
834365	Biolife Solutions Inc	BLFS	Electromedical & Electrotherapeutic Apparatus (3845)	943076866

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1389512	Michael Rice	C/O Biolife Solutions, Inc. 3303 Monte Villa Parkway, Suite 310 Bothell WA 98021	Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-04-11	10,000	$1.90	337,155	No	4	M	Direct
Common Stock	Disposition	2022-04-11	10,000	$19.55	327,155	No	4	S	Direct
Common Stock	Acquisiton	2022-04-12	57,736	$0.00	384,891	No	4	M	Direct
Common Stock	Acquisiton	2022-04-13	10,000	$1.90	394,891	No	4	M	Direct
Common Stock	Disposition	2022-04-13	10,000	$19.06	384,891	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option	Disposition	2022-04-11	10,000	$0.00	10,000	$1.90
Common Stock	Restricted Stock Award	Disposition	2022-04-12	57,736	$0.00	57,736	$0.00
Common Stock	Employee Stock Option	Disposition	2022-04-13	10,000	$0.00	10,000	$1.90

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
70,000	2026-03-15	No	4	M	Direct
0		No	4	M	Direct
60,000	2026-03-15	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of May 21, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.13 to $19.98, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The restricted stock was granted pursuant to BioLife Solutions 2013 Performance Incentive Plan (as amended). In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.61 to $19.28, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
On March 15, 2016, the reporting person was granted an option to purchase 100,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter.